title: Immunotherapy of B-cell malignancies with genetically engineered human CD8+ natural killer T cells.
authors.forename: M
authors.initials: M
authors.lastname: Pieper
authors.forename: C
authors.initials: C
authors.lastname: Scheffold
authors.forename: S
authors.initials: S
authors.lastname: Duwe
authors.forename: C
authors.initials: C
authors.lastname: Rossig
authors.forename: G
authors.initials: G
authors.lastname: Bisping
authors.forename: M
authors.initials: M
authors.lastname: Stelljes
authors.forename: T F
authors.initials: TF
authors.lastname: Tedder
authors.forename: H
authors.initials: H
authors.lastname: Jurgens
authors.forename: W E
authors.initials: WE
authors.lastname: Berdel
authors.forename: J
authors.initials: J
authors.lastname: Kienast
mesh_terms: D018951:Antigens, CD20 / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D005818:Genetic Engineering; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D007694:Killer Cells, Natural / Q000276:immunology*; D016393:Lymphoma, B-Cell / Q000276:immunology / Q000628:therapy*
chemical_list: D018951:Antigens, CD20